Biosimilar Interchangeability: Limited Exclusivity Should Mean Limited Testing – GPhA
This article was originally published in The Pink Sheet Daily
Executive Summary
Although AbbVie is petitioning FDA for expansive definition of 'any given patient' requirement, GPhA and its Biosimilars Council argue that Congress knew how to write the statute more broadly, but didn't.